Asston Pharmaceuticals Ratios

Asston Pharmaceuticals Ltd Ratios

The Asston Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Asston Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Asston Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Asston Pharmaceuticals Ltd (NSE: , BSE: 544445) is currently trading at ₹81, with a market capitalization of ₹662.01M. As a major player in the Distribution services sector and Medical distributors industry, Asston Pharmaceuticals Ltd remains a key stock for fundamental analysis using Asston Pharmaceuticals Ltd Ratios.

Asston Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Asston Pharmaceuticals Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Asston Pharmaceuticals Ltd Ratios.

Historically, the Asston Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

The decline in Asston Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Asston Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.

Historical P/B trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Asston Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Asston Pharmaceuticals Ltd P/S ratio currently stands at 0, an important part of Asston Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

A stable or declining Asston Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Asston Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Asston Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Asston Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

The declining Asston Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Asston Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Asston Pharmaceuticals Ltd EV currently stands at ₹0, representing the total company valuation including debt.

Historical EV trend:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Asston Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Asston Pharmaceuticals Ltd EV/EBITDA ratio is currently 0, a key metric in Asston Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

Stable Asston Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Asston Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Asston Pharmaceuticals Ltd D/E ratio is currently 0.66, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.66
• 2023: 0.95
• 2022: 2.64
• 2021: 3.56

Asston Pharmaceuticals Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Asston Pharmaceuticals Ltd ROE currently stands at 44.21%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 44.21
• 2023: 53.03
• 2022: 72.49
• 2021: 0

Asston Pharmaceuticals Ltd demonstrates strong profitability and efficient capital utilization.

Asston Pharmaceuticals Ltd Ratios Analysis Summary

The Asston Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Asston Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Asston Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.